Up Is Down - Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine Approval.

Avorn, Jerry; Kesselheim, Aaron S

Avorn, Jerry; Kesselheim, Aaron S.

Avorn J; From the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School - both in Boston.
Kesselheim AS; From the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School - both in Boston.

N Engl J Med ; 383(18): 1706-1708, 2020 Oct 29.

Article in English | MEDLINE | ID: covidwho-759648

Subject(s)

Coronavirus Infections/prevention & control; Drug Approval; Drug Industry/trends; Pandemics/prevention & control; Pneumonia, Viral/prevention & control; Viral Vaccines/standards; Betacoronavirus; COVID-19; COVID-19 Vaccines; Humans; Politics; SARS-CoV-2; United States; United States Food and Drug Administration

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Drug Approval / Coronavirus Infections / Drug Industry / Pandemics Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: N Engl J Med Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google